Genmab Revises Financial Guidance

COPENHAGEN, Denmark, Aug. 17, 2009 (GLOBE NEWSWIRE) -- Summary: Genmab Revises
Financial Guidance for 2009.

Genmab A/S (Copenhagen:GEN) announced today it is revising its 2009 financial
guidance. We now expect our 2009 revenue to be approximately DKK 750 million
compared to the previous estimate of DKK 1.2 billion. The reduction in revenue
is primarily due to the exclusion of a milestone payment under the Arzerra(tm)
(ofatumumab) collaboration with GlaxoSmithKline.

With a continued focus on cost control we now anticipate that our operating
expenses will be approximately DKK 1.4 billion, DKK 200 million below our
previous guidance of DKK 1.6 billion. This will result in a revised operating
loss of approximately DKK 650 million, as compared to our previous guidance of
DKK 400 million.

We now expect the cash burn for 2009 to be approximately DKK 700 million
compared to previous guidance of DKK 500 million. Therefore we project a cash
balance at the end of the year of approximately DKK 1,050 million, DKK 200
million below our previous guidance.

2009 Guidance

New Previous
DKK USD DKK USD
Millions Millions Millions Millions
Revenue 750 142 1,200 228
Operating expenses 1,400 265 1,600 304
Operating loss (650) (123) (400) (76)

Cash burn (700) 133 (500) (95)
Cash at end of year* 1,050 199 1,250 237

* Cash, cash equivalents and marketable securities
The estimates above are subject to change due to numerous factors, including the
timing and variation of development activities, related income and costs and
fluctuations in the value of our marketable securities and currency exchange
rates. The financial guidance also assumes that no further significant
agreements are entered into during 2009 that could materially affect the
results.

Conversion of our 2009 guidance has been made using the Danish Central Bank
closing spot rate on June 30, 2009 of USD 1.00 = DKK 5.2689.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery, development and manufacturing teams are using
cutting-edge technology to create and develop products to address unmet medical
needs. Our primary goal is to improve the lives of patients who are in urgent
need of new treatment options. For more information on Genmab's products and
technology, visit www.genmab.com.

This Stock Exchange Release contains forward looking statements. The
words"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or performance
may differ materially from any future results or performance expressed or
implied by such statements. The important factors that could cause our actual
results or performance to differ materially include, among others, risks
associated with product discovery and development, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance of
our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
section "Risk Management" in Genmab's Annual Report, which is available on
www.genmab.com. Genmab does not undertake any obligation to update or revise
forward looking statements in this Stock Exchange Release nor to confirm such
statements in relation to actual results, unless required by law.

Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax-EGFr(tm);
HuMax-IL8(tm); HuMax-TAC(tm); HuMax-HepC(tm); HuMax-CD38(tm); HuMax-CD32b(tm);
HuMax-TF(tm); HuMax-Her2(tm); HuMax-VEGF(tm) and UniBody(r) are all trademarks
of Genmab A/S. Arzerra(tm) is a trademark of GlaxoSmithKline.

Stock Exchange Release no. 32/2009

-0-
CONTACT: Genmab A/S
Helle Husted, Vice President, Investor Relations
+45 33 44 77 30
M: +45 25 27 47 13
h.husted@genmab.com